$2.60
-0.11-4.06%
마지막 업데이트: Oct 16, 7:43 PM
$2.60
-0.11-4.06%
Benzinga
Benzinga
Benzinga
토요일, 10월 17
Benzinga
© 2026 Benzinga | All Rights Reserved
NRX Pharmaceuticals (NRXP) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.12 | $-0.10 | $-0.08 | $-0.05 |
| Actual | $-0.44 | $-0.04 | $0.20 | $-0.27 |
| Surprise | -266.7% | +60.0% | +350.0% | -440.0% |
| Revenue | ||||
| Estimate | $1.5M | $22.9M | $7.0M | $10.8M |
| Actual | $1.1M | $1.1M | $983000 | $242000 |
| Surprise | -28.7% | -95.3% | -86.0% | -97.8% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.18 | $-0.20 | $-0.24 | $-0.14 |
| Revenue | ||||
| Consensus | $1.3M | $2.7M | — | — |
| 회계 분기 | 보고된 날짜 | 실제 EPS | 예상 EPS | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 17, 2026 | $-0.44 | $-0.12 | -266.7 % |
| Q1 | May 15, 2026 | $-0.04 | $-0.10 | 60.0 % |
| Q4 | Mar 23, 2026 | $0.20 | $-0.08 | 350.0 % |
| Q3 | Nov 17, 2025 | $-0.27 | $-0.05 | -440.0 % |
| 회계 분기 | 보고된 날짜 | 실제 수익 | 예상 수익 | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 17, 2026 | $1.10M | $1.54M | -28.7 % |
| Q1 | May 15, 2026 | $1.07M | $22.90M | -95.3 % |
| Q4 | Mar 23, 2026 | $983.00K | $7.04M | -86.0 % |
| Q3 | Nov 17, 2025 | $242.00K | $10.85M | -97.8 % |